MCA Stability Tool

This compatibility recommendation is derived from Aldomet 250mg tablets (Aspen Pharma Trading Ltd) and Methyldopa 250mg tablets (Sovereign Medical Ltd).

Use with caution

Aldomet 500mg tablets (Sigma Pharmaceuticals Plc)

Explore other Methyldopa formulations Explore other Methyldopa 500mg tablets suppliers

Stability Notes

Store in tight, light-resistant containers.

Provenance

This compatibility recommendation is derived from Aldomet 500mg tablets (Aspen Pharma Trading Ltd) and Methyldopa 500mg tablets (Sovereign Medical Ltd).

No Stability Information

Alecensa 150mg capsules (Roche Products Ltd)

Explore other Alectinib formulations Explore other Alectinib 150mg capsules suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Alendronic acid 70mg tablets (A A H Pharmaceuticals Ltd)

Explore other Alendronic acid formulations Explore other Alendronic acid 70mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Alendronic acid 70mg tablets (Alliance Healthcare (Distribution) Ltd)

Explore other Alendronic acid formulations Explore other Alendronic acid 70mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Alendronic acid 70mg tablets (Almus Pharmaceuticals Ltd)

Explore other Alendronic acid formulations Explore other Alendronic acid 70mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Alendronic acid 70mg tablets (Medihealth (Northern) Ltd)

Explore other Alendronic acid formulations Explore other Alendronic acid 70mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Alendronic acid 70mg tablets (Medley Pharma Ltd)

Explore other Alendronic acid formulations Explore other Alendronic acid 70mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

Print this list

Compatible

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Use with caution

There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Incompatible

Medicines under this category are not suitable for use in MCAs.

No Stability Information

These medicines have not been reviewed by SPS.